Genetic Modifiers
Genetic Modifiers - Related Videos
12:45
Testing For Genetically Modified Foods
0 Views •
2023
Source: Laboratories of Margaret Workman and Kimberly Frye - Depaul University Genetic modification of foods has been a controversial issue due to debated concerns over health and environmental safety. This experiment demonstrates technical understanding of how food DNA is genetically identified, allowing for educated decision making about the safety and potential dangers of using genetically modified organisms (GMOs) in food supplies. Polymerase Chain Reaction (PCR) is used to amplify food DNA...
17:50
Preventing the Spread of Malaria and Dengue Fever Using Genetically Modified Mosquitoes
0 Views •
Cited by 10 •
2007
In this candid interview, Anthony A. James explains how mosquito genetics can be exploited to control malaria and dengue transmission. Population replacement strategy, the idea that transgenic mosquitoes can be released into the wild to control disease transmission, is introduced as well as the concept of genetic drive and the design criterion for an effective genetic drive system. The ethical considerations of releasing genetically-modified organisms into the wild are also discussed.
02:55
Genetically Modifying CAR T Cells Using a CRISPR-Cas9 System
0 Views •
2025
The video outlines a process for creating genetically modified CAR T cells through the CRISPR-Cas9 System. Infecting T cells with CRISPR and CAR lentiviruses results in modifications to the target gene and the synthesis of a chimeric antigen receptor or CAR, ultimately leading to the formation of genetically modified CAR T cells.
10:19
Generation of Genetically Modified Mice through the Microinjection of Oocytes
0 Views •
Cited by 19 •
2017
The microinjection of mouse oocytes is commonly used for both classic transgenesis (i.e., the random integration of transgenes) and CRISPR-mediated gene targeting. This protocol reviews the latest developments in microinjection, with a particular emphasis on quality control and genotyping strategies.
09:16
Generation of Genetically Modified Organotypic Skin Cultures Using Devitalized Human Dermis
0 Views •
Cited by 22 •
2015
The goal of this paper is to provide a comprehensive and detailed protocol on how to generate genetically modified human organotypic skin from epidermal keratinocytes and devitalized human dermis.
FAQs
Genetic modifiers can influence phenotype at several biological levels. A variant may change how much of a gene is expressed, alter the activity of its protein product, affect a signaling pathway, or modify interactions between alleles. These routes connect genetic variation to differences in traits, showing that the consequence of one mutation depends on the surrounding molecular and genetic context.
The primary mutation does not act in isolation; modifier variants can change pathway behavior or protein activity, which may amplify or lessen its effect. This helps account for differences in trait expression or disease severity among individuals with a shared mutation. It also provides a framework for studying biological resilience, meaning how systems tolerate or offset harmful genetic changes.
Epistasis is useful because it shifts attention from single-gene effects to relationships among genes and alleles. In this context, one gene or variant can alter the phenotypic consequence of another, while allele interactions can further shape the outcome. Examining these relationships helps connect observed traits with the pathways and genetic context that influence them.
Studies typically combine genetic information with observed traits or disease outcomes. In model organisms and human genetics, investigators examine how genetic differences relate to the effects of a primary mutation, then interpret those differences through gene expression, protein activity, signaling pathways, or allele interactions. This approach links a modifier candidate to a biological mechanism rather than treating phenotype variation as unexplained.
Modifier research can identify pathways associated with disease risk and help explain why clinical outcomes vary. Rather than focusing only on the primary mutation, investigators can consider additional genetic factors that alter its effects. The resulting pathway-level view may clarify why disease severity differs and can reveal biological processes relevant to understanding disease mechanisms.
When modifier effects are understood, they can inform more precise biological and clinical approaches. Findings may support targeted therapies directed at disease-risk pathways while also improving methods for predicting disease. The value lies in accounting for genetic context, so predictions and interventions are not based solely on the expected effect of a primary mutation.